We hypothesize that anti-IGFBP7 therapy holds great promise to improve the response to immune therapy, making it potentially an excellent drug target for combination treatment with immunotherapy for BLCA, which certainly necessitates further studies to verify our speculations. The gene discussed is IGFBP7; the disease is bladder transitional cell carcinoma.